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1207-152 Use of Atropine in Patients With Poor Chronotropic 
Response During Treadmill Stress Testing 
Viiava K. Munaaala, Vamshidhar Guduguntla, Babak Kasravi, Glen Cummings, Julius M. 
Gardin, St. John Hospital & Medical Center, Detroit, Michigan, University of California- 
Irvine, Orange, California. 
Background Treadmill stress testing (TMST) is a valuable diagnostic test for ischemic 
heart disease. However sub-maximal exercise (achieving < 85% of maximum predicted 
heart rate) secondary to fatigue, medications, etc. is a major limitation to its utility. We 
evaluated the usefulness of atropine in decreasing the number of inconclusive tests in 
patients with a poor chronotropic response to TMST. 
Methods The study was comprised of 126 patients undergoing TMST. Atropine was 
administered to subjects experiencing fatigue at sub-maximal exercise in doses of 0.5 
mg/minute until test conclusion (a positive test or target heart rate achieved) or until a 
maximum dose of 2 mg. 
Results Thirty- three of the 126 subjects (26%) required atropine (mean dose 1 mg) dur- 
ing the study; 23 of the 33 subjects (70%) proceeded to achieve their target heart rate 
(n=17) or a positive test (n=6). Mean increase in heart rate after atropine administration 
was 25 beats/min (range 3-53 beats/min); Atropine was required in 39% of patients 
receiving, versus 21% not receiving, beta-blockers (p=0.02). Among subjects receiving 
atropine, a conclusive test was achieved significantly more often in those not receiving 
beta-blockers (94% vs. 46%, p=0.01). No adverse events were associated with the use 
of atropine. 
Conclusion Use of atropine as an adjunct to standard TMST can help decrease the 
number of inconclusive tests - even in patients taking beta-blockers. Larger studies are 
warranted to further define the role of atropine in diagnostic TMST. 
Effect of Beta-Blocker use on TMST outcome in Atropine recipients 
Beta-Blockers Conclusive tests Inconclusive tests 
Yes 7(46%) 8(54%) 
No 14(94%) 1(6%) 
1207-153 Radiofrequency Ablation of Typical Atrial Flutter: 
Immediate Hemodynamic and Cardiorespiratory Benefit 
for the Patient? 
Rainer Schimof, Heycler Omran, Christian Wolpert, Alexander Yang, Susanne Herwig, 
Kyung-Mi Jeong, Thorsten Lewalter, Berndt L~deritz, Department of Medicine- 
Cardiology, University of Bonn, Bonn, Germany. 
Patients with persistent atrial flutter (AFL) can be effectively treated by radiofrequency 
ablation in the cavo-tricuspid isthmus. Despite a more regular excitation and contraction 
than atdal fibrillation the prognostic effect of the ablation therapy and time course of sub- 
maximal hemodynamic and cardiorespiratory function has not been investigated so far. 
Methods: The patients were exercised on a treadmill following the LITE ("Low Intensity 
Treadmill Exercise") protocol before, one day and one month after the procedure. Spiro- 
ergometry and transthoracic echocardiography were performed. With "breath by breath" 
technique oxygen uptake kinetics were analyzed (O2-k), pulmonary artery pressure 
(PAP), left atrial peak A-wave velocity (LAV) and ejection fraction (EF) were determined 
by echocardiography. Results: One month after ablation 15 from 17 patients remained in 
sinusrhythm (mean age 58 +/- 11.2 years). The time to reach steady state, oxygen deficit, 
mean response time of oxygen uptake (MRT) were different at one month in comparison 
to the first day after the procedure. LAV increased significantly after one month (s.Table). 
Despite a more regular excitation and contraction during AFL atrial function remains 
depressed early after regularisstion and recovers delayed. Clinical implication: Radiofre- 
quency ablation therapy of persistent atrial flutter shows a relevant but delayed and not 
immediate hemodynamic and cardiorespiretory benefit at daily submaximal exercise lev- 
els. 
Cardiorespiretory and hemodynamic parameters before 
and after ablation of persistent atrial flutter 
(* p< 0.05) STS (sec) 02-clef (ml) MRT (sec) EF (%) LAY (m/sec) PAP (mmHg) 
before 127+/-21 470+/-110 59+/-18 49+/-10 29+/-10 
1day 110+/-13 390+/-21 62+/-16 49+/-14 0.26+/-0.06 26+/-6 
1month 79+/-14" 280+/-35* 41 +/-16" 56+/-17 0.46+/-0.3* 17+/-4 
1207-154 Interpretation Error of Peak and Anaerobic Threshold 
Oxygen Consumption in Heart Failure Patients During 
Maximal Exercise: Implications for Measuring 
Diminutive Treatment Effects of Intervention 
Donald L. HODDer. Michael Higginbotham, Fred L Ecklund, Julie M. West, Jay 
Millerhagen, Donna Tranchida, Jay Warren, Guidant Corporation, SL Paul, Minnesota, 
Duke University, Durham, North Carolina. 
Background: Various methods of cardiopulmonary exercise tests to determine peak and 
Anaerobic Threshold (AT) VO2 have been developed. While repeated testing is widely 
employed, error in the interpretation of the data has not been well defined. Two inde~ben- 
dent reviewers, A and B, used the following method to determine peak and AT VO2 from 
50 maximal CPX tests performed by 42 heart failure patients (31 males, mean age 65.4; 
11 females, mean age 65,5), with NYHA class II (10), UI (27) and IV (5). 
Methods: Parameters of minute ventilation (VE), oxygen consumption (V02), respiratory 
exchange ratio (RER), carbon dioxide production (VCO2), and the relationships of VE/ 
V02, VENC02 were plotted against time. Peak V02 was determined by averaging the 
V02 values over the last 15 seconds of exercise; the corresponding RER value was used 
to confirm maximal effort. VO2 at AT was determined by standard criteria from the rela- 
tionships of VE/VO2 and VENCO2. 
JACC March  6 ,  2002 
Results: There was no significant difference in mean peak V02, between reviewers, (A: 
13.58 _+ 3.75 vs. B: 13.47 + 3.76 p=. 88), and AT (A: 11.10 + 2.99 vs. B: 10.15 +_ 2.45 p=. 
08). The correlation coefficients for peak VO2 and AT respectively were +0.99 and +0.84. 
Conclusion: A standardized methodology to interpret peak VO2 reduces interpretation 
error and consistent results can be obtained. However, the interpretation of VO2 at AT 
has greater variability and is expected to be less precise for determining serial changes. 
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876-1 Altered Gone Expression Profile in Skeletal Muscle 
After Development of Chronic Heart Failure 
Nicolle Krankel. Volker Adams, Stephan Gielen, Rainer Hambrecht, Gerhard Schuler, 
University of Leipzig, Heart Center Leipzig, Leipzig, Germany. 
Background: Different intrinsic alterations of skeletal muscle (SM) metabolism and gene 
expression have been described in chronic heart failure (CHF). These studies, however 
have only analyzed the differential expression of selected genes, therefore their gain of 
new information is limited. The aim of this study was to compare the gene expression 
profile in SM of rats with CHF and healthy controls. In a second step the findings of the 
animal model were tested in skeletal muscle biopsies of CHF patients. 
Methods: The animals were subjected to either LAD ligation or sham operation. Twelve 
weeks after LAD ligation myocardial infarction was confirmed by echocardiography. 
mRNA was isolated from m. quadriceps of 5 CHF rats and 5 sham operated controls. Dif- 
ferential gone expression was studied by suppression subtractive hybridization. Expres- 
sion of selected genes was further analyzed in SM biopsies of CHF patients and healthy 
controls by quantitative RT-PCR. 
Results: Out of 800 picked clones the differential expression of 120 different sequences 
(15%) could be verified by reverse Northern analysis. Genebank survey revealed the 
identity of 99 genes, whereas 21 sequences did not show homology to any known 
sequence. Out of the 60 non-mitochondrial fragments 24 distinct genes were identified. 
Differential expression of Mss 4, protein phosphatase 2A (PP2A), calsarcin-2 and con- 
taurin-a2 was confirmed by quantitative RT-PCR in SM biopsies of CHF patients and 
healthy controls. Especially PP2a may reduce SERCA activity via dephosphorylation of 
phospholamban and increase the apoptotic rate by dephosphorylation of Bcl-2 and Bad. 
Conclusion: The results of this study indicate that a variety of genes involved in energy 
metabolism, contraction, cell signaling and exocytosis are differentially expressed in SM 
of CHF patients, possibly contributing to the reduction of contractile force and increased 
rate of apoptosis. 
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876-2 Altered Gene Expression of Matrix-Metalloproteinases 
and Tissue Inhibitors of Metalloproteinases in Patients 
Supported by Left Ventricular Assist Devices 
Peter Razeohi, Brian A. Bruckner, Larry O. Thompson, George P. Noon, Keith A. Youker, 
Heinrich Taegtmeyer, University of Texas Houston Medical School, Houston, Texas, 
Bay/or College of Medicine, Houston, Texas. 
Background: Left Ventricular Assist Device (LVAD) treatment improves cardiac function 
and decreases myocardial fibrosis and coltagen content. However, the underlying mech- 
anism is not understood. 
Hypothesis: Gone expression of key regulators of extra-cellular matrix degradation 
changes during LVAD support. 
Methods: Paired myocardial specimens (apex) from 7 patients with end-stage heart fail- 
ure (5 ischemic and 2 dilated cardiomyopathies) were obtained both at the time of 
implantation and explantation of a LVAD device. Using real-time quantitative RT-PCR, we 
measured transcript levels of the matrix-metalloproteinases 1 and 9 (MMP-1, MMP-9) 
and their specific inhibitors, the tissue inhibitor of metallopreteinases 1 and 4 (TIMP-1, 
TIMP-4). Data were normalized to the housekeeping gene beta-ectin. 
Results: There was no uniform response in transcripts investigated from patients sup- 
ported by LVADs. With mechanical unloading, MMP-1 transcript levels increased in 3, did 
not change in 2, and decreased in 2 patients. Gene expression of MMP-9 increased in 2, 
did not change in 1, and decreased in 4 patients, However, patients showing a decrease 
in MMP-9 transcript levels were on support for more than 3 weeks (mean: 9.8 ± 2.8 
